Catalent (NYSE:CTLT) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT) in a report issued on Wednesday. The firm set a “sell” rating on the stock.

CTLT has been the topic of several other research reports. Royal Bank of Canada restated a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a research note on Thursday, July 11th. Barclays boosted their price target on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. Finally, William Blair reiterated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $58.08.

Catalent Price Performance

Shares of CTLT stock opened at $60.39 on Wednesday. The stock’s fifty day simple moving average is $59.33 and its 200 day simple moving average is $57.15. Catalent has a one year low of $31.80 and a one year high of $61.20. The firm has a market cap of $10.93 billion, a price-to-earnings ratio of -9.90, a P/E/G ratio of 1.88 and a beta of 1.15. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.77.

Insider Buying and Selling at Catalent

In other news, CEO Alessandro Maselli sold 9,088 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the transaction, the chief executive officer now directly owns 177,521 shares in the company, valued at $10,431,133.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Matti Masanovich sold 2,993 shares of Catalent stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $56.74, for a total value of $169,822.82. Following the completion of the sale, the chief financial officer now directly owns 33,871 shares in the company, valued at $1,921,840.54. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Alessandro Maselli sold 9,088 shares of the company’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the transaction, the chief executive officer now owns 177,521 shares in the company, valued at $10,431,133.96. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,409 shares of company stock worth $782,923. 0.31% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Catalent

Several institutional investors have recently modified their holdings of CTLT. Lindbrook Capital LLC boosted its position in shares of Catalent by 79.4% in the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after purchasing an additional 208 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Catalent in the second quarter valued at about $42,000. Mather Group LLC. bought a new position in Catalent during the first quarter worth about $52,000. Longfellow Investment Management Co. LLC grew its position in shares of Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after buying an additional 305 shares during the period. Finally, Principal Securities Inc. bought a new stake in shares of Catalent in the 4th quarter valued at about $56,000.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.